Ultragenyx Pharmaceutical (RARE) Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RARE shares.
View RARE analyst ratings or view top-rated stocks.

12 equities research analysts have issued 1 year target prices for Ultragenyx Pharmaceutical's shares. Their RARE share price forecasts range from $50.00 to $142.00. On average, they expect the company's stock price to reach $90.25 in the next twelve months. This suggests a possible upside of 74.8% from the stock's current price.
View analysts price targets for RARE or view top-rated stocks among Wall Street analysts.

Ultragenyx Pharmaceutical's stock was trading at $46.33 at the beginning of the year. Since then, RARE stock has increased by 11.4% and is now trading at $51.62.
View the best growth stocks for 2023 here.

Ultragenyx Pharmaceutical saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 3,490,000 shares, an increase of 17.1% from the April 30th total of 2,980,000 shares. Based on an average daily volume of 637,500 shares, the short-interest ratio is presently 5.5 days. Currently, 5.3% of the shares of the stock are sold short.
View Ultragenyx Pharmaceutical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our RARE earnings forecast.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its earnings results on Thursday, May, 4th. The biopharmaceutical company reported ($2.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.97) by $0.36. The biopharmaceutical company had revenue of $100.50 million for the quarter, compared to analysts' expectations of $103.90 million. Ultragenyx Pharmaceutical had a negative net margin of 187.31% and a negative trailing twelve-month return on equity of 149.75%. The firm's quarterly revenue was up 25.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.19) EPS.

ETFs with the largest weight of Ultragenyx Pharmaceutical (NASDAQ:RARE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), Motley Fool Mid-Cap Growth ETF (TMFM) and SPDR S&P Biotech ETF (XBI).

Ultragenyx Pharmaceutical updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $425.00 million-$450.00 million, compared to the consensus revenue estimate of $435.57 million.

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Ultragenyx Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (7.22%), BlackRock Inc. (6.90%), RTW Investments LP (6.04%), Price T Rowe Associates Inc. MD (5.01%), State Street Corp (3.89%) and Clearbridge Investments LLC (3.82%). Insiders that own company stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends.

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RARE stock can currently be purchased for approximately $51.62.

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $3.66 billion and generates $363.33 million in revenue each year. The biopharmaceutical company earns $-707,420,000.00 in net income (profit) each year or ($10.25) on an earnings per share basis.

The company employs 1,311 workers across the globe.

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for the company is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810.